Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27kip1 at the transcriptional and posttranscriptional levels

Cancer Research

Volumn 68, Issue 13, 2008, Pages 5076-5085

  Morishita, Daisuke ^a   Katayama, Ryohei ^a   Sekimizu, Kazuhisa ^a   Tsuruo, Takashi ^a   Fujita, Naoya ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROTEASOME; PROTEIN KINASE; PROTEIN KINASE PIM 1; PROTEIN KINASE PIM 2; PROTEIN KINASE PIM 3; THREONINE; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; PROTO ONCOGENE PROTEINS PIM; PROTO-ONCOGENE PROTEINS PIM; SMALL INTERFERING RNA;

ARTICLE; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; ENZYME ASSAY; ENZYME BINDING; ENZYME INHIBITION; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ACTIVE TRANSPORT; AMINO ACID SEQUENCE; CELL CULTURE; CELL CYCLE; CELL NUCLEUS; CELL PROLIFERATION; CELL STRAIN K 562; CHEMISTRY; CONSENSUS SEQUENCE; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVE SITE; GENETIC TRANSFECTION; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; SITE DIRECTED MUTAGENESIS;

ACTIVE TRANSPORT, CELL NUCLEUS; AMINO ACID SEQUENCE; CATALYTIC DOMAIN; CELL CYCLE; CELL NUCLEUS; CELL PROLIFERATION; CELLS, CULTURED; CONSENSUS SEQUENCE; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOWN-REGULATION; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; K562 CELLS; MUTAGENESIS, SITE-DIRECTED; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-PIM-1; RNA, SMALL INTERFERING; THREONINE; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 48549096958     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0634     Document Type: Article

References (49)

1. van Lohuizen M, Verbeek S, Krimpenfort P, et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 1989;56:673-82.
2. Selten G, Cuypers HT, Berns A. Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas. EMBO J 1985;4:1793-8.
3. Amaravadi R, Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 2005;115:2618-24.
4. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
5. Allen JD, Verhoeven E, Domen J, van der Valk M, Berns A. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene 1997;15:1133-41.
6. Cohen AM, Grinblat B, Bessler H, et al. Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma 2004;45:951-5.
7. Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS. Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res 2005;3:443-51.
8. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
9. Liso A, Capello D, Marafioti T, et al. Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. Blood 2006;108:1013-20.
10. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001;412:341-6.
11. Traverse-Glehen A, Verney A, Baseggio L, et al. Analysis of BCL-6, CD95, PIM1, RHO/TTF and PAX5 mutations in splenic and nodal marginal zone B-cell lymphomas suggests a particular B-cell origin. Leukemia 2007;21:1821-4.
12. Kumar A, Mandiyan V, Suzuki Y, et al. Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. J Mol Biol 2005;348:183-93.
13. Lilly M, Sandholm J, Cooper JJ, Koskinen PJ, Kraft A. The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene 1999;18:4022-31.
14. Yan B, Zemskova M, Holder S, et al. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem 2003;278:45358-67.
15. Mikkers H, Nawijn M, Allen J, et al. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 2004;24:6104-15.
16. Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, Kuchino Y. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem 1999;274:18659-66.
17. Bachmann M, Kosan C, Xing PX, Montenarh M, Hoffmann I, Moroy T. The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C. Int J Biochem Cell Biol 2006;38:430-43.
18. Bachmann M, Hennemann H, Xing PX, Hoffmann I, Moroy T. The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpoint. J Biol Chem 2004;279:48319-28.
19. Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J Biol Chem 2002;277:28706-13.
20. Kip1 at threonine 198 by p90 ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic localization. J Biol Chem 2003;278:49254-60.
21. Liang J, Zubovitz J, Petrocelli T, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002;8:1153-60.
22. Kip1 localization depends on the tumor suppressor protein tuberin. Hum Mol Genet 2007;16:1541-56.
23. Kip1 at threonine 157 and modulation of its cellular localization. Nat Med 2002;8:1145-52.
24. Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002;8:1136-44.
25. Kip1 at G1 phase. Nat Cell Biol 2004;6:1229-35.
26. KIP1 promoter transactivation. Mol Cancer Res 2005;3:163-9.
27. Kip1. Nature 2000;404:782-7.
28. Montagnoli A, Fiore F, Eytan E, et al. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 1999;13:1181-9.
29. Kip1. Cell 1996;85:721-32.
30. Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-30.
31. INK4d expression. Oncogene 2008;27:1677-86.
32. Liang H, Hittelman W, Nagarajan L. Ubiquitous expression and cell cycle regulation of the protein kinase PIM-1. Arch Biochem Biophys 1996;330:259-65.
33. Bullock AN, Debreczeni J, Amos AL, Knapp S, Turk BE. Structure and substrate specificity of the Pim-1 kinase. J Biol Chem 2005;280:41675-82.
34. Peng C, Knebel A, Morrice NA, et al. Pim kinase substrate identification and specificity. J Biochem 2007;141:353-62.
35. Adam M, Pogacic V, Bendit M, et al. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL. Cancer Res 2006;66:3828-35.
36. Kim KT, Baird K, Ahn JY, et al. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 2005;105:1759-67.
37. Saris CJ, Domen J, Berns A. The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J 1991;10:655-64.
38. Kip1. EMBO J 2004;23:1934-42.
39. Nieborowska-Skorska M, Hoser G, Kossev P, Wasik MA, Skorski T. Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. Blood 2002;99:4531-9.
40. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-68.
41. Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol 2001;21:952-65.
42. Brunet A, Kanai F, Stehn J, et al. 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J Cell Biol 2002;156:817-28.
43. Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 2002;1593:45-55.
44. Li YY, Popivanova BK, Nagai Y, Ishikura H, Fujii C, Mukaida N. Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res 2006;66:6741-7.
45. van der Lugt NM, Domen J, Verhoeven E, et al. Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2. EMBO J 1995;14:2536-44.
46. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999;1:193-9.
47. Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J Biol Chem 2002;277:14355-8.
48. Rodier G, Montagnoli A, Marcotullio LDi, et al. p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J 2001;20:6672-82.
49. Scheijen B, Ngo HT, Kang H, Griffin JD. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. Oncogene 2004;23:3338-49.